Intelligence Platform
Patents
Browse 140 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 10471051
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted patentUS 10441646
Infectious plasmodium sporozoites grown in vitro
granted patentUS 10368569
Natural sweetener
granted patentUS 10316039
P2X3 and/or P2X2/3 compounds and methods
granted patentUS 10316080
Protein-polymer-drug conjugates
granted patentUS 10272146
Purified plasmodium and vaccine compositions
granted patentUS 10226468
Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/m
granted patentUS 10226535
Auristatin compounds and conjugates thereof
granted patentUS 10188654
Uses of pyrimido-pyridazinones to treat cancer
granted patentUS 10183944
Pyrimido-pyridazinone compounds and methods of use thereof
granted patentUS 10174039
P2X3 and/or P2X2/3 compounds and methods
granted patentUS 10143695
Pyrrolobenzodiazepines and conjugates thereof
granted patentUS 10130618
Pharmaceutical combinations of dabigatran and proton pump inhibitors
granted patentUS 10111925
Formulations comprising plant extracts
granted patentUS 10111912
Herbal formulations
granted patentUS 10111957
Inhalation compositions comprising glucose anhydrous
granted patentUS 10105316
Inhalation compositions comprising muscarinic receptor antagonist
granted patentUS 9980931
Use of glycyl glutamine against depression
granted patentUS 9944637
P2X3 and/or P2X2/3 compounds and methods
granted patentUS 9943609
Protein-polymer-drug conjugates
granted patentUS 9931389
Genetic attenuation of plasmodium by B9 gene disruption
granted patentUS 9913869
Formulations comprising herbal extracts
granted patentUS 9908879
P2X3 and/or P2X2/3 compounds and methods
granted patentUS 9896445
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted